Case studies

Read more about how we partner with like-minded, science-led organisations.

We have been partnering with the Max-Planck Society and consortium companies for several years.

In 2014, we established a chemistry ‘satellite unit’ for cardiovascular and metabolic diseases at the Max Planck Institute of Molecular Physiology in Dortmund, Germany. Here, AstraZeneca scientists are working side-by-side with academic researchers to study new modalities chemistry. This novel strategic alliance aims to discover innovative approaches to drug discovery by combining the strengths of industry and academia. Our focus is on novel chemistry and chemical biology in areas of new modality chemistry such as stabilised peptides, macrocycles and conjugation chemistry.

AstraZeneca has collaborated with Karolinska Institutet in Sweden, one of the world’s leading medical research universities, for many years on different projects.

In 2013, we created a joint centre for research on cardiovascular and metabolic diseases. This goes deeper than the usual industry-academia partnership, as scientists from both partners work side-by-side in a dedicated university unit to develop new therapies for people in need. The Integrated Cardio Metabolic Centre (ICMC) aims to identify and validate novel targets within cardiometabolic diseases, focusing on three strategic research areas: heart failure, diabetes and chronic kidney disease across both small molecules and biologics.